Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for Tecnis PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) used in cataract surgery.

Tecnis PureSee IOL addresses both cataract-related vision loss and the effects of presbyopia, which happens when the eyes gradually lose the ability to see objects clearly up close. According to the company, it’s the first and only FDA-approved EDOF IOL with no warning on loss on contrast sensitivity.

Aspheric monofocal IOLs are considered the benchmark for preserving contrast sensitivity. By maintaining contrast sensitivity comparable to an aspheric monofocal IOL, Tecnis PureSee IOL helps patients have the visual clarity and confidence they expect while benefitting from an extended range of vision, according to J&J.

The new IOL is built on the company’s Tecnis platform, which combines advanced optics with proprietary material. It mitigates the effects of presbyopia with extended depth of focus, allowing distance and intermediate vision with some near vision. J&J said Tecnis PureSee reduces reliance on glasses after surgery, with 97% of patients reporting no very bothersome visual disturbances.

“Today marks an exciting milestone for people living with cataracts. The approval of the TECNIS PureSee IOL gives surgeons an important new lens option, reflecting our deep commitment to innovation that delivers high patient satisfaction and supports vision solutions tailored to individual lifestyle needs,” said Peter Menziuso, Company Group Chairman, Vision, Johnson & Johnson. “Cataract surgery is often a once-in-a-lifetime opportunity for patients to restore and enhance their vision. With the addition of TECNIS PureSee IOL to our portfolio, we can help even more patients regain not just sight, but the quality, range, and visual performance they expect from a Johnson & Johnson product.”

Last month, the company announced the U.S. launch of its Cereglide 42 and Cereglide 57 aspiration catheters, along with the Innerglide 7 delivery aid, as the latest in its aspiration-first stroke portfolio.